Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 28, 2017. The document serves as a transaction notification regarding a specific equity award to a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a single transaction involving the award of 12,105 Ordinary Shares to Mrs. V A Whyte (SVP & Company Secretary) under the 2017 Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The transaction is noted as a conditional award subject to meeting performance criteria over a three-year period.
Investor Verification Checklist
- Verify the vesting conditions and performance criteria for the 2017 Performance Share Plan.
- Confirm the total number of shares awarded to Mrs. V A Whyte (12,105 shares).
- Note the transaction date of July 27, 2017, and the reference price of £15.31 per share.
- Check subsequent filings for the actual vesting status of these shares after the three-year period.